Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

Rhea-AI Summary

Viz.ai has entered into a multi-year partnership with Bristol Myers Squibb (BMY) to implement an AI algorithm designed to detect and triage patients for hypertrophic cardiomyopathy (HCM). The AI algorithm, which is under FDA review following a de novo classification request, aims to streamline the identification process for patients who may be at risk. HCM affects millions globally, and timely diagnosis can significantly improve outcomes. The collaboration will enhance capabilities within the Viz.ai Cardio Suite, which is currently utilized by around 1,300 U.S. hospitals.

Positive

• Partnership with Bristol Myers Squibb to develop AI technology for HCM detection.
• FDA has accepted the de novo classification request for the AI algorithm.
• Potential to enhance patient outcomes through improved diagnostic capabilities.
• Integration with the Viz.ai Cardio Suite across 1,300 hospitals in the U.S.

Negative

• None.

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM

SAN FRANCISCO--(BUSINESS WIRE)-- Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (Viz^TM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.

Viz.ai Announces Agreement with Bristol Myers Squibb on Hypertrophic Cardiomyopathy (Graphic: Business Wire)

“HCM is the most common inherited heart disease with an estimated prevalence between 1 in 200 and 1 in 500, and one of the leading causes of sudden cardiac death in people under age 35,” said David Huneycutt, M.D., F.A.C.C., a cardiologist at HCA Healthcare’s TriStar Centennial Medical Center in Nashville, Tenn. and an enterprise-wide cardiovascular physician director. “Since a high percentage of patients remain undiagnosed, it is critical that we find solutions to identify patients with suspected HCM sooner.”

HCM is defined by thickened heart muscle, which can make it harder for the heart to pump blood. It is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure. HCM is estimated to impact an estimated 750,000 people in the United States and 20 million worldwide.¹

“At BMS, we believe that the use of AI to detect key, subtle characteristics in bio signals to aid physicians in the screening, diagnosis, treatment and monitoring of diseases will have a critical and positive impact on patients’ lives,” said Suhas Krishna, Vice President, Head of Digital Health Product Management, Bristol Myers Squibb. “We are excited to continue building momentum in our support of Viz.ai’s research and development program. The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”

Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care. Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals, which is expected to advance cardiac care coordination through a mobile-based electrocardiogram viewer, built with timely AI-powered alerts and communication tools. The Viz.ai Intelligent Care Coordination Platform, which includes Viz.ai Cardio Suite, is adopted by nearly 1,300 hospitals in the U.S. Viz.ai has placed Viz HCM at several hospitals, including select HCA Healthcare facilities, under research agreements to further evaluate the product in clinical practice. The company plans to launch Viz HCM broadly upon FDA clearance.

“Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time,” said Dr. Chris Mansi, CEO at Viz.ai. “Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”

For more information on Viz HCM for research, please visit https://www.viz.ai/research/hcm.

^*Viz HCM not available for sale. Investigational use only
¹ Maron BJ. N Engl J Med. 2018; 379:655-68.​​

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and helps improve outcomes. Backed by real-world clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005086/en/

Ariane Lovell

ariane.lovell@finnpartners.com

Source: Viz.ai, Inc.

FAQ

What is the purpose of the agreement between Viz.ai and Bristol Myers Squibb (BMY)?

The agreement aims to deploy an AI algorithm for detecting and triaging patients suspected of having hypertrophic cardiomyopathy (HCM).

What does Viz HCM do?

Viz HCM automatically reviews ECGs to identify suspected cases of HCM and notifies cardiologists for timely clinical action.

When was the FDA de novo classification request submitted for Viz HCM?

The de novo classification request was submitted by Viz.ai, and it has been accepted by the FDA for review.

How prevalent is hypertrophic cardiomyopathy (HCM) in the United States?

HCM is estimated to affect around 750,000 people in the United States.

How many hospitals in the U.S. utilize the Viz.ai platform?

The Viz.ai platform is adopted by nearly 1,300 hospitals across the United States.